TARSUS PHARMACEUTICALS, INC. Shareholders' Equity
TARSUS PHARMACEUTICALS, INC. (TARS) had Shareholders' Equity of $346.73 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $346.73M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $348.95M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $343.43M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $335.08M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $346.73M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $348.95M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $343.43M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $335.08M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $332.61M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $342.46M 10-Q · filed 2026-08-06 |
| 2024-12-31 | $224.53M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $237.48M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $252.25M 10-Q · filed 2025-11-04 |
| 2024-03-31 | $275.21M 10-Q · filed 2025-11-04 |
| 2023-12-31 | $196.99M 10-K · filed 2026-02-23 |
| 2023-09-30 | $213.66M 10-Q · filed 2024-11-13 |
| 2023-06-30 | $147.73M 10-Q · filed 2024-11-13 |
| 2023-03-31 | $173.40M 10-Q · filed 2024-11-13 |
| 2022-12-31 | $192.90M 10-K · filed 2026-02-23 |
| 2022-09-30 | $202.63M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $221.50M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $149.20M 10-Q · filed 2023-11-09 |
| 2021-12-31 | $166.73M 10-K · filed 2025-02-25 |
| 2021-09-30 | $179.14M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $192.47M 10-Q · filed 2022-11-09 |
| 2021-03-31 | $183.23M 10-Q · filed 2022-11-09 |
| 2020-12-31 | $165.98M 10-K · filed 2023-03-17 |
| 2020-09-30 | -$17.83M 10-Q · filed 2021-11-10 |
| 2020-06-30 | -$11.04M 10-Q · filed 2021-11-10 |
| 2020-03-31 | -$7.96M 10-Q · filed 2021-11-10 |
| 2019-12-31 | -$6.00M 10-K · filed 2022-03-14 |
| 2019-09-30 | -$4.60M 10-Q · filed 2020-11-25 |
| 2019-06-30 | -$3.92M 10-Q · filed 2020-11-25 |
| 2019-03-31 | -$3.10M 10-Q · filed 2020-11-25 |
| 2018-12-31 | -$1.35M 10-K · filed 2021-03-31 |
| 2017-12-31 | -$44.00K 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |